- Home
- AARD vs DDD Comparison
AARD vs DDD Comparison
Compare AARD & DDD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AARD | DDD |
|---|---|---|
| Founded | 2017 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer peripheral equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.1M | 303.8M |
| IPO Year | N/A | 2003 |
Fundamental Metrics
Financial Performance| Metric | AARD | DDD |
|---|---|---|
| Price | $5.80 | $2.45 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 2 |
| Target Price | ★ $19.63 | $4.75 |
| AVG Volume (30 Days) | 325.0K | ★ 1.7M |
| Earning Date | 01-01-0001 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 109.79 |
| EPS | N/A | ★ 0.19 |
| Revenue | N/A | ★ $386,902,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.31 |
| P/E Ratio | ★ N/A | $6.83 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.74 | $1.48 |
| 52 Week High | $17.94 | $3.80 |
Technical Indicators
Market Signals| Indicator | AARD | DDD |
|---|---|---|
| Relative Strength Index (RSI) | 24.24 | 63.86 |
| Support Level | $4.74 | $1.80 |
| Resistance Level | $15.88 | $2.70 |
| Average True Range (ATR) | 0.54 | 0.15 |
| MACD | -0.55 | 0.05 |
| Stochastic Oscillator | 12.99 | 81.08 |
Price Performance
Historical ComparisonAbout AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About DDD 3D Systems Corporation
3D Systems Corp provides comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and services, including maintenance, advanced manufacturing and applications engineering. The company's segments include Healthcare Solutions and Industrial Solutions. It generates maximum revenue from the Industrial segment. It conducts business through various offices and facilities located throughout the Americas, EMEA, and APAC; generating a vast majority of revenues from the Americas.